Novartis, Schering-Plough to develop new inhaler option
Schering-Plough and Novartis will develop a once-daily inhaled combination therapy for asthma and COPD, the firms said.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.